Our Development Pipeline
TMB-001, topical isotretinoin in Timber’s patented IPEG™ delivery system, is being developed for the treatment of moderate to severe subtypes of Congenital ichthyosis (CI). In a Phase 2a study, treatment with TMB-001 was shown to be well tolerated with no evidence of systemic absorption of isotretinoin. There was also a clear signal of efficacy with patients showing a reduction in scaling and IGA after eight to twelve weeks. These data have been submitted for peer-reviewed publication. In 2018, the FDA awarded $1.5 million to support Phase 2a and Phase 2b clinical trials evaluating TMB-001 through its Orphan Products Grant program. Currently, Timber has an active Phase 2b clinical trial; data are expected during the Fall 2021.
If you are interested in any of Timber’s ongoing clinical research programs, please contact firstname.lastname@example.org.